FDA approves GSK- XenoPort postherpetic neuralgia therapy
A single 12-week principal efficacy trial and two supportive studies that met their respective primary endpoints evaluated the efficacy and safety of Horizant. A dosage of 600mg twice
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).